UCB transfers back to Recordati the rights for the sale of Corifeo(R) (Lercanidipine) in Germany

26-Apr-2006

UCB announced that it has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany of Corifeo®, an antihypertensive calcium channel blocker, for a payment to UCB of 10 million euros.

"This transaction is another step taken by UCB in its strategy to focus on innovation for specialists particularly in the fields of the central nervous system, inflammation (including allergy) and oncology," declared Bill Robinson, Executive Vice President Global Operations of UCB.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance